LDL Receptor and ApoE Are Involved in the Clearance of ApoM-associated Sphingosine 1-Phosphate*

Makoto Kurano‡, Kazuhasha Tsukamoto§, Masumi Hara‡, Ryunosuke Ohkawa§, Hitoshi Ikeda‡, and Yutaka Yatomi‡

From the Department of Clinical Laboratory Medicine, Graduate School of Medicine, University of Tokyo, 7-3-1, Hongo, Bunkyo-ku, Tokyo 113-8655, the Department of Metabolism, Diabetes and Nephrology, Aizu Medical Center, Fukushima Medical University, 21-2, Maeda, Yazawaji, Higashimachi, Aizuwakamatsu, Fukushima 969-3482, the Department of Clinical Laboratory, University of Tokyo Hospital, 7-3-1, Hongo, Bunkyo-ku, Tokyo 113-8655, and the Department of Medicine IV, Misonokuchi Hospital, Teikyo University School of Medicine, 3-8-3, Misonokuchi, Takatsu-ku, Kawasaki, Kanagawa 213-0001, Japan

Background: A positive correlation exists between sphingosine 1-phosphate (S1P) and LDL cholesterol.

Results: Hepatic LDL receptor overexpression decreased plasma S1P together with apoM in wild-type mice, but not in apoE-deficient mice.

Conclusion: LDL receptor is involved in the clearance of S1P, utilizing apoE as a ligand.

Significance: We propose the novel role of LDL receptor and apoE in the clearance of S1P.

Sphingosine 1-phosphate (S1P) is a vasoactive lipid mediator that is speculated to be involved in various aspects of atherosclerosis. About 70% of circulating plasma S1P is carried on HDL, and several pleiotropic properties of HDL have been ascribed to S1P. In the previous study with human subjects, however, LDL cholesterol or apoB, but not HDL cholesterol or apoA-I, had a significant positive correlation with the plasma S1P level, suggesting that the metabolic pathway for LDL might have some roles in the metabolism of S1P. In this study, we analyzed the association between LDL receptor, an important protein in the clearance of LDL, and circulating S1P. We observed that in LDL receptor-overexpressing mice, the plasma S1P levels as well as apolipoprotein M (apoM), a carrier of S1P, were decreased and that exogenously administered C17S1P were decreased and that exogenously administered C17S1P. We observed that in LDL receptor-overexpressing mice, the plasma S1P levels as well as apolipoprotein M (apoM), a carrier of S1P, were decreased and that exogenously administered C17S1P were decreased and that exogenously administered C17S1P.
TABLE 1
Multiple regression analysis for plasma S1P

| Model A     | β    | p value |
|-------------|------|---------|
| RBC (10^6/μl) | 43.537 | 0.403   |
| Alb (g/dl)   | 85.249 | 0.351   |
| LDL-C (mg/dl) | 0.456 | 0.301   |
| Sex (not selected) | 0.987  |         |
| Platelet (10^9/μl) | 0.600  |         |
| HDL-C (mg/dl) | 0.059  |         |
| TG (mg/dl)   | 0.999  |         |

| Model B     | β    | p value |
|-------------|------|---------|
| Alb (g/dl)  | 88.679 | 0.365   |
| RBC (10^6/μl) | 40.530 | 0.375   |
| ApoB (mg/dl) | 0.607  | 0.288   |
| Sex (not selected) | 0.696  |         |
| Platelet (10^9/μl) | 0.484  |         |
| ApoA-I (mg/dl) | 0.221  |         |
| ApoA-II (mg/dl) | 0.814  |         |
| ApoC-II (mg/dl) | 0.911  |         |
| ApoC-III (mg/dl) | 0.884  |         |
| ApoE (mg/dl) | 0.553  |         |

Recently, apolipoprotein M (apoM), an apolipoprotein carried mainly on HDL (18), has been proved to be a carrier of S1P (19). Interestingly, in several human studies, the apoM level exhibited a significant, positive correlation not only with the HDL cholesterol level, but also with the LDL cholesterol level (20), although most plasma apoM molecules exist on HDL (18, 21). In addition, the clearance of human apoM-containing HDL is reportedly retarded in LDLr-deficient mice, suggesting that apoM is cleared through the LDL receptor (22).

In view of the results from these reports, the LDL receptor might clear S1P as well as apoM-containing lipoproteins; if the LDL receptor clears S1P bound to apoM-containing lipoproteins, it is rational that plasma S1P levels are correlated with LDL cholesterol, because LDL receptor is established to clear LDL, and therefore S1P and LDL cholesterol undergo clearance through the same protein, LDL receptor. We have settled these problems by employing mice models and in vitro experiments.

EXPERIMENTAL PROCEDURES

Generation of Recombinant Adenoviruses—Human LDL receptor (LDLr) cDNA was cloned from a CDNA library for human liver (9505, TaKaRa Bio Inc., Shiga, Japan) using the following primers: forward primer, 5'-ttccagctagcagcagctgct-3'; and reverse primer, 5'-gaatgagctgtacctggt-3'. Human LDLr adenovirus (Ad-LDLr) was constructed using the AdEasy system (Stratagene, La Jolla, CA) and purified using CsCl gradient centrifugation. Adenovirus coding apoM (Ad-apoM) and its control blank adenovirus (Ad-null) (23) and adenovirus coding apoE (Ad-apoE) and its control LacZ, expressing adenovirus (Ad-LacZ) (24) have been described previously.

Animal Experiments—C57BL/6 mice and apoE-deficient mice were obtained from CLEA Japan (Tokyo, Japan) and Sankyo Lab Service Co. (Tokyo, Japan), respectively. Ten-week-old C57BL/6 mice or apoE-deficient mice were injected with adenovirus via the tail vein at a dose of 2.5 × 10^8 pfu/g of body weight. The mouse experiments were performed on the fifth day after viral administration. All animal experiments were conducted in accordance with the guidelines for Animal Care and were approved by the animal committee of The University of Tokyo.

Analyses of Total Cholesterol Level in the Plasma—Five days after injection of the adenoviruses, the mice were subjected to a 6-h fast and blood samples were subsequently collected. The total cholesterol level was measured using enzymatic methods (439–17501, WAKO Pure Chemical Industries). To fractionate the lipoproteins, the plasma samples were pooled together and then separated using fast protein liquid chromatography (FPLC) utilizing a Superose 6 column.

Analysis of Clearance of Lipoproteins Containing C17,S1P and ApoM in Vivo—The conditional medium of apoM-overexpressing HepG2 cells (prepared as described previously (23)) or apoM-depleted HepG2 cells (prepared with siRNA against apoM (sc-61978, Santa Cruz Biotechnology)), the total volumes of which were 12 ml/dish, were concentrated to about 500 μl/dish by centrifugation and purification using Amicon Ultra-15 (UFC901008, Millipore Co., Bedford, MA) (25). Then, 160 μg of the conditioned medium C17,S1P bound to apoM-containing lipoproteins through the tail vein. Plasma samples of the mice were collected at 30 min after administration.

Separation of ApoE-rich and ApoE-poor HDL—ApoE-rich and apoE-poor HDL were separated with heparin-Sepharose affinity chromatography (5-ml HiTrap heparin HP (GE Healthcare Bio-Science AB, Uppsala, Sweden)); HDL were isolated from the plasma using standard ultracentrifugation followed by dialysis against PBS and 2 mg of HDL was applied to the column. The column was washed with PBS containing 0.05 m NaCl (flow rate, 0.5 ml/min) and the eluted fraction was utilized as apoE-poor HDL, then washed with PBS containing 0.3 m NaCl (flow rate, 0.5 ml/min); the eluted fraction was utilized as apoE-rich HDL. They were again dialyzed against PBS before the use for the cell experiments. Total cholesterol and phospholipid levels of each HDL were measured with enzymatic methods (439–17501 and 433–36201, respectively, WAKO Pure Chemical Industries).

Cell Experiments—HepG2 cells were obtained from American Type Culture Collection (Manassas, VA). The cells were then cultured in DMEM (D5796, Sigma) supplemented with 10% fetal bovine serum (FBS; 10099-141, Invitrogen) and 1% penicillin/streptomycin (15070-063, Invitrogen).

To examine modulation of the medium apoM level by overexpression of the LDL receptor or apoE, HepG2 cells were infected with adenoviruses at an multiplicity of infection of 25. After 3 days, the medium was replaced with serum-free medium, and then 12 h later, the medium was collected and subjected to the analyses.

To examine the clearance of C17,S1P on HepG2 cells, evaporated C17,S1P was delivered on LDLr-overexpressing cells or control cells with the condensed conditional medium of apoM-overexpressing HepG2 cell or apoM-depleted HepG2 cell, PBS containing 0.4% fatty acid-free albumin, apoE-poor HDL, or
apoE-rich HDL as the vehicle. The final concentration of \( C_{17}\)-S1P in the prepared medium was 5 \( \mu \)M for condensed conditional medium and albumin. For apoE-poor/rich HDL, the final concentration of 250 nM \( C_{17}\)-S1P was bound to 200 \( \mu \)g/ml (final concentration) of HDL. Then, \( C_{17}\)-S1P complexes were added to the cells. After 10 or 30 min, the medium and cells were collected and the \( C_{17}\)-S1P levels were measured.

To examine the effects of pitavastatin, we treated the cells with 10 \( \mu \)M pitavastatin (L-0250-022, Chemtech Laboratory, Inc., Tokyo, Japan) with or without 30 mM mevalonate (M4667, Sigma), as described previously (26). Evaporated \( C_{17}\)-S1P was delivered using the condensed conditional medium of apoM-overexpressing HepG2 cells. The final concentration of \( C_{17}\)-S1P in the prepared medium was 10 \( \mu \)M. After 10 min, the medium was collected and the \( C_{17}\)-S1P levels were measured.

Measurement of S1P and \( C_{17}\)-S1P—The contents of S1P and \( C_{17}\)-S1P in the plasma and medium were determined using two-step lipid extraction followed by HPLC separation, as described previously (27). Briefly, samples were sonicated in 3 ml of methanol/chloroform (2:1) with an internal standard for 30 min. After adding 2 ml of chloroform, 2.1 ml of 1 mM KCl, and 100 \( \mu \)l of 3 \( \times \) NaOH, samples were centrifuged and the alkaline upper phase (3.8 ml) was collected to new tubes, to which 4 ml of chloroform and 200 \( \mu \)l of concentrated HCl were added. The resultant lower chloroform phases (3.5 ml) formed under these new acidic conditions were collected and evaporated under nitrogen gas and resolved in methanol, followed by HPLC separation with a TSKgel ODS-80TM column (0017202, Tosoh, Tokyo, Japan). For measurement of the S1P content, we used C17-S1P (860641P, Avanti Polar Lipids) as an internal standard, whereas for \( C_{17}\)-S1P content, we used FTY720-phosphate (10006408, Cayman Chemical, Ann Arbor, MI).

Western Blotting—Cellular proteins and liver proteins were extracted using RIPA lysis buffer (25 mM Tris-HCl, pH 7.6, 1% Nonidet P-40, 0.1% SDS, 150 mM NaCl, 0.02% sodium deoxycholate, 1 mM orthovanadate, 1 mM PMSF, and protease inhibitor mixture (11836153001, Roche Applied Science). Membranous proteins were prepared as described previously (26). Western blotting was performed using 30 \( \mu \)g of the cellular or liver proteins according to a standard method. To analyze the proteins in the medium, the amount of medium subjected to Western blotting was adjusted according to the cellular protein level. For the plasma analysis, a volume corresponding to 0.5 \( \mu \)l of plasma was used for the Western blotting analysis. The following antibodies were used: anti-human apoM antiserum (developed in a previously reported paper (23)), anti-mouse apoM antibody (A00954, GenScript Co, Piscataway, NJ), anti-apoA-I antibody, anti-apoE antibody (AB740 and AB947, Chemicon International Inc., Temecula, CA), anti-apoB antibody, anti-mouse albumin antibody (sc-11795 and sc-46293, Santa Cruz Biotechnology), anti-LDL receptor antibody (10007665, Cayman Chemical Co.), anti-human albumin antibody (E80–129A, Bethyl Laboratories, Inc., Montgomery, TX), anti-pan cadherin antibody (RB-9036-PD, Thermo Fisher Scientific Inc., Fremont, CA), and anti-\( \beta \)-actin antibody (PM053, MBL, Nagoya, Japan). The intensities of the bands were measured by ImageJ (from the NIH).

Real Time PCR—Total RNAs extracted from murine livers with the GenElute Mammalian Total RNA Miniprep kit (Sigma) were subjected to reverse transcription with SuperScript II enzyme (Invitrogen). Quantitative PCR was performed using an ABI 7300 Real-time PCR System (Applied Biosystems) for apoM (Mm00444525_m1), ABCA1 (Mm00442646_m1), ABCG1 (Mm00437390_m1), SR-BI (Mm00450234_m1), and \( \beta \)-actin (Mm00607939_s1). The expression levels of the genes of interest were adjusted to those of the endogenous \( \beta \)-actin mRNA as a control.

ELISA—The apoM level in the mice plasma was measured with mouse apolipoprotein M ELISA kit (CSB-EL001947MO, Cusabio Biotechnology Co., Wuhan, China), according to the manufacturer’s protocol.

Statistical Analysis—All data were statistically analyzed using SPSS (Chicago, IL). The results were expressed as the mean \pm S.E. Differences between two groups were evaluated using Student’s \( t \) test, and differences among more than two groups were assessed using a one-way analysis of variance, followed by the Scheffe’s test as a post hoc test. \( p \) values less than 0.05 were deemed statistically significant.

RESULTS

LDL Receptor Overexpression Decreased the Plasma Levels of S1P—First, we overexpressed the LDL receptor in the liver of wild-type mice using adeno viral gene transfer (Fig. 1A) and examined the modulation of plasma S1P levels. As expected, the plasma total cholesterol level was reduced (Fig. 1B). FPLC analyses revealed that not only the LDL cholesterol level but also the HDL cholesterol level was reduced (Fig. 1C). As shown in Fig. 1D, the plasma S1P level was markedly reduced in LDLr-overexpressing mice. Among lipoprotein fractions, the amount of S1P carried on HDL was especially decreased (Fig. 1E and F), whereas the amount of S1P in lipoprotein-depleted plasma was not significantly modulated in LDLr-overexpressing mice (Fig. 1F).

LDL Receptor Overexpression Decreased the Plasma Levels of ApoM—Because 70% of plasma S1P is distributed on HDL and apoM, which is a potent carrier of S1P (19), and apoM is reported to be cleared through LDL receptor (22), we next investigated the modulation of apoM by LDL receptor overexpression. As shown in Fig. 2, A, C, and D, the apoM level was significantly reduced, along with apoB and apoE levels (Fig. 2, A–C) in LDLr-overexpressing mice, which was concordant with the previous report (22). A decline in the apoM level, as well as in the apoE level, was also observed when the LDL receptor was overexpressed in HepG2 cells (Fig. 2, F and G). We further analyzed the apoM level in FPLC fractions and observed that the apoM level, which was distributed mainly within the HDL fraction in wild-type mice, was dramatically reduced in the HDL fraction (Fig. 2E), which was consistent with the modulation of S1P in FPLC fractions by LDL receptor overexpression (Fig. 1E). Regarding the apoE distribution, apoE levels in the LDL and HDL fractions were also reduced.

LDL Receptor Is Involved in S1P Clearance in Vivo—The results obtained using LDLr-overexpressing mice prompted us to investigate whether the LDL receptor might also remove S1P as well as apoM from circulation, in addition to its role in LDL
We next examined the clearance of C17S1P bound to apoM-containing lipoproteins in LDLr-overexpressing mice. We prepared apoM-containing lipoproteins as described under “Experimental Procedures,” in which evaporated C17S1P was dissolved. C17S1P was distributed among lipoproteins, especially in HDL fractions (fraction 37–45), which were abundant in apoM (data not shown).

We injected C17S1P bound to apoM-containing lipoproteins into LDLr-overexpressing mice or control mice through the tail vein and found that at 30 min after administration, both C17S1P and human apoM levels were lower in the LDLr-overexpressing mice (Fig. 3, A, C, and D). In LDLr-overexpressing mice, the plasma C17S1P content was reduced in almost all the FPLC fractions; however, the C17S1P level in the HDL fraction was particularly reduced (Fig. 3B), along with a reduced amount of human apoM in the HDL fraction (Fig. 3E). When we injected C17S1P bound to apoM-depleted lipoproteins, prepared using siRNA against apoM, we observed no difference between mice infected with control virus and LDLr-overexpressing mice (Fig. 3F); this siRNA was confirmed to suppress the apoM protein level in the medium of HepG2 cells by 73%.

**LDL Receptor Is Involved in S1P Clearance in Vitro**—We also performed similar experiments in vitro; the clearance of C17S1P bound to apoM-containing lipoproteins on LDLr-overexpressing HepG2 cells or control cells was investigated. As shown in Fig. 4, A and B, C17S1P in the medium was cleared more rapidly on the LDLr-overexpressing HepG2 cells, whereas the cellular C17S1P content increased to a greater degree on the LDLr-overexpressing HepG2 cells. The medium levels of apoM and apoE also decreased faster on LDLr-overexpressing HepG2 cells than control cells.
on the control cells (Fig. 4, C–E). In contrast, when C17S1P was bound to fatty acid-free albumin or apoM-depleted lipoproteins, no difference was observed in either the medium or cellular levels of C17S1P between the LDLr-overexpressing cells and on control cells (Fig. 4, F–I), demonstrating that the LDL receptor-mediated clearance of S1P might only be specific to S1P bound to apoM-containing lipoproteins.

The LDL receptor is up-regulated by treatment with HMG-CoA reductase inhibitor. Therefore, we also investigated the effect of pitavastatin on the clearance of C17S1P bound to apoM-containing lipoproteins. As shown in Fig. 5, A and B, the LDLr protein level in the cellular membranous fractions was increased by treatment with pitavastatin and this up-regulation was reversed by mevalonate. Concordant with the results from LDLr-overexpressing HepG2 cells, the apoM level in the medium was reduced by treatment with pitavastatin, and this effect was reversed using mevalonate (Fig. 5, C and D). The clearance of C17S1P bound to apoM-containing lipoproteins was faster in the cells treated with pitavastatin (Fig. 5E).

ApoE Overexpression Decreased the Plasma Levels of S1P and ApoM—Next, we investigated how the LDL receptor clears S1P bound to apoM-containing lipoproteins. As shown in Figs. 2, A, C, F, and G, and 4, C and E, the apoE level was also reduced, along with the apoM level, in LDLr-overexpressing mice or cells. Considering that although apoB100 is known to be a ligand for the LDL receptor, apoE can also serve as a ligand for the LDL receptor on both TG-rich lipoproteins (28, 29) and apoE-rich HDL (30, 31), we next investigated the effects of apoE on the plasma S1P and apoM levels. First, we examined the plasma S1P and apoM levels in apoE-deficient and wild-type mice. As shown in Fig. 6, A and B, the plasma S1P level was higher in apoE-deficient mice than in the wild-type mice, whereas the plasma apoM level was not significantly modulated in the apoE-deficient mice. ApoE-deficient mice are mice with
an extremely different lipoprotein metabolism including S1P and apoM from wild-type mice; in apoE-deficient mice, S1P and apoM are distributed not only to HDL, but also to VLDL/LDL (Fig. 6, D and E), and the hepatic expression of apoM is lower in apoE-deficient mice (Fig. 6C), whereas the expression levels of the key enzymes involved in S1P metabolism were not modulated (data not shown). Therefore, these results did not rule out the possibility that apoE might influence the metabolism of S1P bound to apoM-containing lipoproteins.

Therefore, we next investigated the effects of apoE overexpression on plasma S1P and apoM levels and found that the plasma S1P and apoM levels were significantly reduced in the apoE-overexpressing mice (Fig. 7, A, B, D, and E), together with a reduced cholesterol level of LDL (Fig. 7C) and apoB (Fig. 7, C and F). The plasma S1P and apoM levels were reduced in the HDL fraction, although the apoE level was increased in almost all FPLC fractions (Fig. 7, G and H). This decrease in the apoM level during apoE overexpression was also observed in apoE-overexpressing HepG2 cells (Fig. 7, I and J). These effects of the overexpression of apoE on the plasma S1P and apoM levels suggest that apoE might have some roles in accelerating the clearance of S1P bound to apoM-containing lipoproteins.

LDL Receptor Overexpression Did Not Affect the Plasma Levels of S1P or ApoM in ApoE-deficient Mice—Considering the results of our experiments, apoE on apoM-containing lipoproteins, which carry S1P, might serve as a ligand for the LDL receptor. To confirm this hypothesis, we overexpressed the LDL receptor in apoE-deficient mice (Fig. 8A). Overexpression of the LDL receptor reduced the LDL/LDL cholesterol levels (Fig. 8B); however, the plasma apoM and S1P levels were not reduced in LDLr-overexpressing apoE-deficient mice (Fig. 8, C–F). Interestingly, overexpression of the LDL receptor in apoE-deficient mice tended to result in increase in the plasma S1P and apoM levels especially in HDL fractions (Fig. 8, G and H) along with the increase in HDL (Fig. 8B) and apoA-I (Fig. 8, D and E) amounts. Although the mechanism behind has not been elucidated, one possible explanation is that overexpression of the LDL receptor may decrease the expression level of hepatic scavenger receptor class B, type I (SR-BI), a receptor for HDL (Fig. 8I). Therefore, apoE on apoM-containing lipoproteins is essential for the clearance of apoM and S1P through the LDL receptor, and apoE may serve as a ligand for the LDL receptor.
LDL Receptor Is Involved in the Clearance of S1P Bound to ApoE-rich HDL, but Not to ApoE-poor HDL—Finally, we separated apoE-rich HDL with heparin-Sepharose affinity chromatography as described under “Experimental Procedures.” The S1P and other lipid contents in apoE-rich HDL and apoE-poor HDL are shown in Table 2. We investigated the clearance of C_{17}S1P bound to apoE-rich HDL and C_{17}S1P bound to apoE-poor HDL on LDLr-overexpressing HepG2 cells or control cells. Although apoM was rather rich in apoE-poor HDL as shown in Fig. 7A, the clearance of C_{17}S1P was faster on LDLr-overexpressing HepG2 cells only when C_{17}S1P was bound to apoE-rich HDL (Fig. 7B and C). These results also support that...
apoE has a crucial role in the clearance of S1P bound to apoM-containing lipoproteins through the LDL receptor.

**DISCUSSION**

S1P is mainly carried on HDL (≈70%), followed by albumin (≈30%), in circulation, and several anti-atherosclerotic properties of HDL have been ascribed to S1P carried on HDL. Contrary to this established distribution of S1P among lipoproteins, we previously reported that the plasma S1P level is not correlated with the HDL cholesterol or apoA-I levels (17). Interestingly, the plasma S1P level is significantly and positively correlated with LDL cholesterol and apoB levels. The similar correlation between plasma S1P and LDL cholesterol level is also recently reported from other group (32). These observations suggest that the metabolic pathway involved in the clearance of LDL, such as LDL receptor, might have some roles in the clearance of S1P.

In this study, we overexpressed LDL receptor and observed that the plasma S1P level, especially in HDL fractions, was markedly decreased. Recently, apoM, an apolipoprotein dis-
tributed mainly on HDL, has been elucidated to be a carrier of S1P (19), and the previous reports demonstrated that apoM was cleared through LDL receptor (22, 33). In our models, we also observed that apoM was decreased in LDLr-overexpressing mice, as well as S1P (Figs. 2, 3, and 4, A–E), suggesting that S1P bound to apoM might be cleared through the LDL receptor. The main function of the LDL receptor is the uptake of LDL from the circulation into the liver; therefore, it seems reasonable that the plasma S1P level should be positively related to the LDL cholesterol level. Actually, the treatment of HepG2 cells with an HMG-CoA reductase inhibitor, statin, accelerated the clearance of C17-S1P bound to apoM-containing lipoproteins (Fig. 5), which is consistent with the results from a previous study demonstrating that statin treatment decreased the apoM level in human subjects (34). This result may suggest a limitation of the clinical benefit of statin: namely, the problem of...
residual risk. Statin lowers the LDL cholesterol level to almost the same level as that seen in healthy subjects and prevents cardiovascular diseases; however, statin cannot completely eliminate ischemic heart diseases (35). In *in vitro* experiments, S1P exhibited anti-atherosclerotic properties and attributes of the pleiotropic properties of HDL. Therefore, S1P might be a useful target for overcoming the issue of residual risk.

In this study, we also demonstrated that both the plasma S1P and apoM levels decreased in apoE-overexpressing mice (Fig. 7). These results suggested that apoE plays some role in accelerating the clearance of plasma S1P and apoM. Both apoB100

### TABLE 2

**S1P contents in apoE-poor HDL and apoE-rich HDL**

One mg of HDL prepared from healthy subjects (*n* = 4) was separated into apoE-poor HDL and apoE-rich HDL, as described under "Experimental Procedures." S1P, total cholesterol (TC), and total phospholipid (PL) contents of whole HDL, ApoE-poor HDL, and ApoE-rich HDL were determined. Data were expressed as the mean ± S.E.

|            | Whole HDL | ApoE-poor HDL | ApoE-rich HDL |
|------------|-----------|---------------|---------------|
| S1P (ng)   | 89.5 ± 8.1| 68.8 ± 9.5    | 19.6 ± 2.9    |
| TC (μg)    | 133.3 ± 7.7| 83.8 ± 4.8   | 23.3 ± 3.5    |
| PL (μg)    | 398.5 ± 25.7| 335.6 ± 32.9| 341. ± 4.5    |
| S1P/PL (ng/μg)| 272.1 ± 12.4| 272.1 ± 12.4| 272.1 ± 12.4  |
| TC/PL (μg/μg)| 335.4 ± 10.4| 254.0 ± 17.7| 682.1 ± 19.9  |

residual risk. Statin lowers the LDL cholesterol level to almost the same level as that seen in healthy subjects and prevents cardiovascular diseases; however, statin cannot completely eliminate ischemic heart diseases (35). In *in vitro* experiments, S1P exhibited anti-atherosclerotic properties and attributes of the pleiotropic properties of HDL. Therefore, S1P might be a useful target for overcoming the issue of residual risk.

In this study, we also demonstrated that both the plasma S1P and apoM levels decreased in apoE-overexpressing mice (Fig. 7). These results suggested that apoE plays some role in accelerating the clearance of plasma S1P and apoM. Both apoB100
possibility is that in apoE-deficient mice, apoM and S1P are apoE-poor HDL (30, 31). Because apoM and S1P exist mainly on HDL and minimally on apoB-containing lipoproteins (5, 18), apoE on apoM-containing lipoproteins might serve as a ligand for the LDL receptor. Actually, LDL receptor overexpression in apoE-deficient mice did not decrease either the plasma apoM or S1P levels (Fig. 8). The result that the clearance of C17S1P bound to apoE-rich HDL, but not that bound to apoE-poor HDL, was influenced by LDL receptor also supports the crucial role of apoE in the clearance of S1P bound to apoM (Fig. 9). Regarding LDL receptor-mediated apoM clearance, Christoffersen et al. (22) have suggested the other mechanism in the previous paper; apoM is shuttled from HDL to LDL and the apoM is cleared with LDL particles. The pathway proposed in the previous article may also exist in the present study; S1P levels in IDL/LDL fractions (fraction 26–35) were decreased in LDL receptor overexpressing apoE-deficient mice (Fig. 8G), although the total plasma S1P level and S1P levels in HDL fractions (fraction 41–46) were rather increased in LDLr-overexpressing apoE-deficient mice.

Although the in vivo experiments with apoE-overexpressing mice and LDLr-overexpressing apoE-deficient mice and in vitro experiments using apoE-poor and apoE-rich HDL supported that the LDL receptor might utilize apoE as a ligand in the clearance of S1P bound to apoM-containing lipoproteins, the result from the experiment comparing apoE-deficient mice with wild-type mice seemed inconsistent with this hypothesis. One possible explanation is that hepatic apoM expression level in apoE-deficient mice was lower than that in wild-type mice, suggesting that lower apoM production blurred retarded clearance of apoM in apoE-deficient mice (Fig. 6C). Another possibility is that in apoE-deficient mice, apoM and S1P are distributed not only to HDL but also to VLDL/IDL fractions, whereas most of them are distributed to HDL fractions in wild-type mice (Fig. 6, D and E). Because VLDL/IDL, especially that of apoE-deficient mice, possesses different structures and undergoes a different metabolism from HDL, the modulations of total plasma apoM and S1P might be somewhat different in apoE-deficient mice. Although the distributions of apoM and S1P were different in apoE-deficient mice, the result that the S1P and apoM levels in HDL fractions were not decreased in LDLr-overexpressing apoE-deficient mice (Fig. 8, G and H) supported that apoE is necessary for the LDL receptor to clear S1P bound to apoM-containing HDL.

Another interesting observation in the present study was that overexpression of the LDL receptor in apoE-deficient mice tended to increase HDL cholesterol as well as S1P and apoM in HDL fractions (Fig. 8, G and H). Although the mechanisms for this are not yet elucidated, hepatic expression of SR-BI, an HDL receptor, was found to be significantly decreased in LDLr-overexpressing apoE-deficient mice (Fig. 8I), which might increase HDL cholesterol as well as apoM and S1P in HDL fractions. These results suggest that SR-BI may also have some important roles in the metabolism of S1P bound to apoM-containing lipoproteins. Further studies are needed to elucidate this possibility. In conclusion, the LDL receptor is involved in the clearance of S1P bound to apoM-containing lipoproteins, possibly utilizing apoE as a ligand, which may be related to the paradoxical correlation between the plasma S1P level and apoB-containing lipoproteins.

REFERENCES
1. Jacob, A. O., and Choudhury, R. P. (2012) Targeting HDL-cholesterol to reduce residual cardiovascular risk. Curr. Opin. Lipidol. 23, 172–174
2. Schofield, J. D., France, M., Ammori, B., Liu, Y., and Soran, H. (2013) High-density lipoprotein cholesterol raising: does it matter? Curr. Opin. Cardiol. 28, 464–474
3. Brewer, H. B., Jr. (2011) Clinical review: The evolving role of HDL in the...
treatment of high-risk patients with cardiovascular disease. J. Clin. Endocrinol. Metab. 96, 1246–1257
4. Yatomi, Y. (2006) Sphingosine 1-phosphate in vascular biology: possible therapeutic strategies to control vascular diseases. Curr. Pharm. Des. 12, 575–587
5. Okajima, F. (2002) Plasma lipoproteins behave as carriers of extracellular sphingosine 1-phosphate: is this an atherogenic mediator or an anti-atherogenic mediator? Biochim. Biophys. Acta 1582, 132–137
6. Rodríguez, C., González-Diez, M., Badimón, L., and Martínez-González, J. (2009) Sphingosine-1-phosphate: a bioactive lipid that confers high-density lipoprotein with vasculo-protective mediated by nitric oxide and pros-tycycin. Thromb. Haemost. 101, 665–673
7. Goetzl, E. J. (2001) Pleiotropic mechanisms of cellular responses to biologically active lysophospholipids. Prostaglandins 64, 11–20
8. Kimura, T., Tomura, H., Mogi, C., Kuwabara, A., Aimirinit, A., Ishizuka, T., Sekiguchi, A., Ishihara, M., Im, D. S., Sato, K., Murakami, M., and Okaji- jima, F. (2006) Role of scavenger receptor class B type I and sphingosine 1-phosphate receptors in high density lipoprotein-induced inhibition of adhesion molecule expression in endothelial cells. J. Biol. Chem. 281, 37457–37467
9. Argraves, K. M., and Argraves, W. S. (2007) HDL serves as a S1P signaling platform mediating a multitude of cardiovascular effects. J. Lipid Res. 48, 2325–2333
10. Igarashi, J., Bernier, S. G., and Michel, T. (2001) Sphingosine 1-phosphate and activation of endothelial nitric-oxide synthase: differential regulation of Akt and MAP kinase pathways by EDG and bradykinin receptors in vascular endothelial cells. J. Biol. Chem. 276, 12420–12426
11. Nofer, J. R., van der Giet, M., Tölle, M., Wolinska, I., von Wnuck Lipinski, A., Ström, J., Sevvana, M., Egerer-Sieber, C., Müller, Y. A., Hla, T., Nielsen, L. B., and Dahlbäck, B. (2003) Isolation and characterization of human apolipoprotein M-containing lipoproteins. Blood 102, 821–832
12. Kurano, M., Tsukamoto, K., Ohkawa, R., Harasawa, Y., Ikeda, H., and Yatomi, Y. (2013) Liver involvement in sphingosine 1-phosphate dysregulation revealed by adenosine receptor overexpression of apolipoprotein M. Atherosclerosis 229, 102–109
13. Garcia, J. G., Liu, F., Verin, A. D., Birukova, A., Dechert, M. A., Gerthoffer, W. T., and English, D. (2001) Sphingosine 1-phosphate receptor 5. J. Clin. Invest. 113, 569–581
14. Sanchez, T., Estrada-Hernandez, T., Paik, J. H., Wu, M. T., Venkataraman, K., Brinkmann, V., Claffey, K., and Hla, T. (2003) Phosphorylation and action of the immunomodulator FTY720 inhibits vascular endothelial cell growth factor-induced vascular permeability. J. Biol. Chem. 278, 47281–47290
15. Sanchez, T., and Hla, T. (2004) Structural and functional characteristics of S1P receptors. J. Cell Biol. 92, 913–922
16. Argraves, K. M., Sethi, A. A., Gazzolo, P. J., Wilkerson, B. A., Remaley, A. T., Bröcker-Preuss, M., Budde, T., Erbel, R., Heusch, G., and Levi, K. (2010) Sphingosine 1-phosphate levels in plasma and HDL are altered in coronary artery disease. Basic Res. Cardiol. 105, 821–832
17. Okahara, K., Nakamura, K., Kukuma, S., Hosogaya, S., Ozaki, Y., Tozuka, M., Osimi, N., Yokota, H., Ikeda, H., and Yatomi, Y. (2008) Plasma sphingo- sine–1-phosphate levels in healthy subjects: close correlation with red blood cell parameters. Ann. Clin. Biochem. 45, 356–363
18. Xu, N., and Dahlbäck, B. (1999) A novel human apolipoprotein (apoM). J. Biol. Chem. 274, 31286–31290
19. Christoffersen, C., Obinata, H., Kumaraswamy, S. B., Galvani, S., Ahs- ström, J., Sevvarna, M., Egerer-Sieber, C., Muller, Y. A., Hla, T., Nielsen, L. B., and Dahlbäck, B. (2011) Endothelium-protective sphingosine-1-phosphate provided by HDL-associate apolipoprotein M. Proc. Natl. Acad. Sci. U.S.A. 108, 9613–9618
20. Argraves, K. M., and Argraves, W. S. (2007) HDL serves as a S1P signaling platform mediating a multitude of cardiovascular effects. J. Lipid Res. 48, 2325–2333
21. Christoffersen, C., Nielsen, L. B., Argraves, W. S., Andersson, A. J., Johansen, A. H., and Dahlbäck, B. (2006) Isolation and characterization of human apolipo- protein M-containing lipoproteins. J. Lipid Res. 47, 1833–1843
22. Christoffersen, C., Benn, M., Christensen, P. M., Gords, P. L., Roebroek, A. J., Frieke-Schmidt, R., Tybjaerg-Hansen, A., Dahlbäck, B., and Nielsen, L. B. (2012) The plasma concentration of HDL-associated apoM is influ-enced by LDL receptor-mediated clearance of apoB-containing particles. J. Lipid Res. 53, 2198–2204
23. Kurano, M., Tsukamoto, K., Ohkawa, R., Harasawa, Y., Ikeda, H., and Yatomi, Y. (2013) Liver involvement in sphingosine 1-phosphate dysregulation revealed by adenosine receptor overexpression of apolipoprotein M. Atherosclerosis 229, 102–109